Ustekinumab

Adult: For moderate to severe cases in patients who have had inadequate response with, lost response to, or were intolerant of conventional therapy or tumour necrosis factor-α (TNF-α) antagonist or have contraindications to such therapies: Induction of remission: Patients weighing ≤55 kg: 260 mg as a single dose; >55-≤85 kg: 390 mg as a single dose; >85 kg: 520 mg as a single dose. Doses are given via IV infusion over at least 1 hour. Maintenance of remission: 90 mg via SC inj, initiated 8 weeks after the IV dose, then repeated every 8 or 12 weeks thereafter according to response. Treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).

Adult: For moderate to severe cases in patients who have had inadequate response with, lost response to, or were intolerant of conventional therapy or biologic agent or have contraindications to such therapies: Induction of remission: Patients weighing ≤55 kg: 260 mg as a single dose; >55-≤85 kg: 390 mg as a single dose; >85 kg: 520 mg as a single dose. Doses are given via IV infusion over at least 1 hour. Maintenance of remission: 90 mg via SC inj, initiated 8 weeks after the IV dose, then repeated every 8 or 12 weeks thereafter according to response. Treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).

Adult: For moderate to severe cases in patients who have failed to respond to, have a contraindication to, or are intolerant of other systemic therapies (e.g. methotrexate, ciclosporin, psoralen and ultraviolet A [PUVA]): Patients weighing ≤100 kg: 45 mg at weeks 0 and 4, then every 12 weeks thereafter; >100 kg: 90 mg at weeks 0 and 4, then every 12 weeks thereafter. Discontinue therapy if there is no response after 28 weeks. Treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Child: For moderate to severe cases in patients who are inadequately controlled by or are intolerant of other systemic therapies or phototherapeis: ≥6 years Patients weighing <60 kg: 0.75 mg/kg at weeks 0 and 4, then every 12 weeks thereafter; ≥60-≤100 kg: 45 mg at weeks 0 and 4, then every 12 weeks thereafter; >100 kg: 90 mg at weeks 0 and 4, then every 12 weeks thereafter. Discontinue therapy if there is no response after 28 weeks. Treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).

Adult: As monotherapy or in combination with methotrexate in patients with inadequate response to previous non-biological DMARD therapy: 45 mg at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, in patients weighing >100 kg: 90 mg at weeks 0 and 4, then every 12 weeks thereafter. Discontinue therapy if there is no response after 28 weeks. Treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).